A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
University of Alabama at Birmingham
Qilu Pharmaceutical Co., Ltd.
City of Hope Medical Center
National Cancer Institute (NCI)
Genmab
AstraZeneca
Imunon
Imunon
AstraZeneca
AstraZeneca
Jiangsu Cancer Institute & Hospital
Ohio State University Comprehensive Cancer Center
AstraZeneca
NRG Oncology
Eli Lilly and Company
OHSU Knight Cancer Institute
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Hospices Civils de Lyon
National Cancer Institute (NCI)
Zhejiang Cancer Hospital
University Health Network, Toronto
National Cancer Institute (NCI)
Blueprint Medicines Corporation
Tesaro, Inc.
National Cancer Institute (NCI)
AbbVie
Merck Sharp & Dohme LLC
Wake Forest University Health Sciences
Maastricht University Medical Center
Merck Sharp & Dohme LLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Eli Lilly and Company
University of Washington
AGO Study Group
Merck Sharp & Dohme LLC
Toray Industries, Inc
Tesaro, Inc.
AstraZeneca
CanariaBio Inc.
The University of Hong Kong
The University of Hong Kong
University of Pittsburgh
Universitaire Ziekenhuizen KU Leuven
The University of Hong Kong
Novakand Pharma AB
Tongji Hospital
Loma Linda University
Jonsson Comprehensive Cancer Center